The German-Austrian AML Study Group (AMLSG) carried out a prospective study to stratify treatments by analyzing mutations in RUNX1-RUNX1T1, CBFB-MYH11, PML-RARA, KIT, FLT3-ITD, NPM1, and MLL within 48 h of initial diagnosis. This evidence concerns the gene RUNX1 and acute myeloid leukemia.